Начало・Списък с акции・Beam Therapeutics Inc

Beam Therapeutics Inc

Отворен

СекторЗдравеопазване

26.92 -4.71

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

26.6

Максимум

28.42

Ключови измерители
By Trading Economics
Приходи	-339M -94M
Продажби	-82M 32M
EPS	-0.91
Марж на печалбата	-297.177
Служители	522
EBITDA	-349M -89M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+87.9% upside

Дивиденти
By Acuity
Следващи печалби	2.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-425M 2.7B
Предишно отваряне	31.63
Предишно затваряне	26.92

Настроения в новините

By Acuity

86%

14%

320 / 340 Класиране в Healthcare

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.08.2026 г., 23:06 ч. UTC

Beam Therapeutics Inc. shares are lower in after-market hours, following a session low shortly after the open, despite three consecutive higher daily closes.

3.08.2026 г., 19:16 ч. UTC

Correlated Moves

News

Beam Therapeutics is rising amid a broader market rally, with a market cap of $2.64 billion and $1.2 billion in liquidity to support operations.

31.07.2026 г., 19:16 ч. UTC

Correlated Moves

Beam Therapeutics shares are lower, reflecting a decline in first-quarter results and broader sector weakness. The stock remains near the lower end of its one-month range.

30.07.2026 г., 23:06 ч. UTC

Beam Therapeutics Inc shares are higher in after-hours trading, advancing since Thursday's close, despite remaining below the 20-day moving average.

29.07.2026 г., 22:51 ч. UTC

Beam Therapeutics shares are lower in after-market hours following a volatile session, amid broader market uncertainty after the Federal Reserve's interest rate decision.

28.07.2026 г., 23:51 ч. UTC

Beam Therapeutics Inc shares are lower in after-market trading, experiencing unusual volatility amid broader market declines and positioned below its 20-day moving average.

27.07.2026 г., 23:06 ч. UTC

Beam Therapeutics Inc shares are higher in after-market hours, despite a broader decline in trading. No specific news was identified to explain the increase.

24.07.2026 г., 19:26 ч. UTC

Event

Correlated Moves

Beam Therapeutics is declining today, reflecting broader market trends, with the Russell 2000 Index down. The stock remains below its 20-day moving average.

23.07.2026 г., 09:51 ч. UTC

News

Beam Therapeutics is higher in pre-market trading, driven by significant upcoming clinical milestones, including the global BEAM-302 trial and an FDA application for risto-cel.

22.07.2026 г., 23:46 ч. UTC

Beam Therapeutics shares higher in after-market trading, advancing since Wednesday's close. The stock remains below its 20-day moving average amid broader market influences.

21.07.2026 г., 18:06 ч. UTC

Correlated Moves

Beam Therapeutics shares are higher today, reflecting positive sentiment in small-cap stocks amid anticipation of upcoming earnings results from major companies.

20.07.2026 г., 23:56 ч. UTC

Beam Therapeutics Inc is higher in after-market trading, showing notable strength since Monday's close. No specific news was identified to explain the movement.

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

87.9% нагоре

12-месечна прогноза

Среден 53.27 USD 87.9%

Висок 80 USD

Нисък 26 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Beam Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

320 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.